<DOC>
	<DOCNO>NCT01408888</DOCNO>
	<brief_summary>The purpose study study effect LY2189265 body absorbs process Type 2 Diabetes Mellitus ( T2DM ) drug ( sitagliptin ) sitagliptin affect LY2189265 take together . The duration participation study expect approximately 61 day . The study require 2 clinic confinement ( one 2 night one 19 night duration ) . The study involve 3 injection , subcutaneous , 1.5 milligram ( mg ) LY2189265 18 daily dos 100 mg sitagliptin tablet administer orally .</brief_summary>
	<brief_title>A Study LY2189265 Sitagliptin Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>male female , diagnose T2DM ( Type 2 Diabetes Mellitus ) ≥3 month prior screen male participant female partner childbearing potential , partner pregnant breastfeeding , agree use reliable method contraception time first dose 3 month last dose investigational product , determine investigator . The method may one following : condom spermicidal agent male participant sterilization true abstinence ( line participant 's usual lifestyle choice ; withdrawal calendar method consider acceptable ) female participant childbearing potential ( , postmenopausal permanently sterilize [ , tubal occlusion , hysterectomy , bilateral salpingectomy ] ) . Such participant require use contraception must test negative pregnancy time enrollment . Postmenopausal define least 1 year post cessation menses ( without alternative medical cause ) least 1 year spontaneous amenorrhea , follicle stimulate hormone ( FSH ) ≥40 milliinternational units/milliliter ( mIU/mL ) female participant undergone sterilization tubal ligation : agree use condom conjunction spermicidal gel , foam , cream , film suppository time screen 3 month last dose investigational product . Such participant must also test negative pregnancy time enrollment body mass index ( BMI ) 23.0 40.0 kilograms/meter square ( kg/m^2 ) , inclusive , time screen T2DM control diet exercise alone , stable dose metformin Immediate Release ( IR ) least 4 week prior screen , metformin Extended Release ( ER ) capable/willing switch onto metformin IR wash prior first dose investigational product , sulfonylureas , acarbose ( disaccharidase inhibitor ) , thiazolidinediones , meglitinides capable/willing wash prior first dose investigational product fast blood glucose value screen ≤15.3 millimoles/liter ( mmol/L ) ( 275 milligrams/deciliter [ mg/dL ] ) glycosylated hemoglobin A1c ( HbA1c ) value screening ( within 4 week prior screen ) 6.5 % 10 % clinical laboratory test result within normal reference range population within normal reference range investigator site , result acceptable deviation judge clinically significant investigator . Abnormalities serum glucose , serum lipid , urinary glucose , urinary protein consistent T2DM acceptable . creatinine clearance ( CrCl ) great 50 milliliters/minute ( mL/min ) screening estimate CockcroftGault formula venous access sufficient allow blood sample per protocol reliable willing make available duration study willing follow study procedure currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product , concurrently enrol type medical research judge scientifically medically compatible study know allergy glucagonlikepeptide 1 ( GLP1 ) relate compound , include LY2189265 sitagliptinrelated compound component either formulation person previously complete withdrawn study study investigate LY2189265 3 month prior screen receive glucagonlike peptide incretin mimetics 3 month prior screen take insulin , chlorpropamide , alphaglucosidase inhibitor within 30 day prior screen abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study poorly control hypertension ( systolic blood pressure [ BP ] &gt; 160 millimeter mercury [ mmHg ] and/or diastolic BP &gt; 100 mmHg ) and/or evidence labile BP include symptomatic postural hypotension history presence respiratory , hepatic , renal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data history presence cardiovascular disorder ( include myocardial infarction , cerebrovascular accident , venous thromboembolism , arrhythmia [ judge investigator clinically significant ] , angina ) within last year , symptom sign congestive heart failure , expect require coronary artery bypass surgery angioplasty history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) gastrointestinal disorder , example relevant esophageal reflux gall bladder disease , gastrointestinal disease impact gastric empty ( GE ) ( , gastric bypass surgery , pyloric stenosis , exception appendectomy ) could aggravate GLP1 analog dipeptidyl peptidase4 ( DPP4 ) inhibitor . Participants dyslipidemia , participant cholecystolithiasis ( removal gall stone ) and/or cholecystectomy ( removal gall bladder ) past , sequela , may include study discretion screen physician exist medical condition might interfere interpretation data , include history gastrointestinal surgery ( exception appendectomy perform 12 month ago ) , peptic ulceration , gastrointestinal bleeding , diabetic gastroparesis , ulcerative colitis , Crohn 's disease , Irritable Bowel Syndrome ( IBS ) , gastric bypass , laparoscopic gastric banding show evidence significant active neuropsychiatric disease 2 episode severe hypoglycemia within last 6 month prior screen personal family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC regularly us know drug abuse and/or show positive finding urinary drug screen intend start new concomitant medication study , include overthecounter herbal medication , regularly use drug directly reduce gastrointestinal motility and/or regularly use systemic corticosteroid oral , intravenous , intramuscular route , potent , inhale , intranasal steroid know high rate systemic absorption show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen donate blood 500 milliliter ( mL ) within last month prior screening average weekly alcohol intake exceed 21 unit per week ( male age 65 ) 14 unit per week ( male 65 female ) , unwilling stop alcohol consumption Day 3 period last pharmacokinetic ( PK ) sample take period , limit alcohol intake maximum 2 units/day day screen followup . ( 1 unit = 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) smoke 10 cigarette ( equivalent nicotine ) per day , unwilling refrain smoking day LY2189265/sitagliptin administration unable abide Clinical Research Unit ( CRU ) restriction inpatient day participant , opinion investigator , way unsuitable participate study medical condition , medical history take medication contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>